FILING ANALYSIS · TUESDAY, NOVEMBER 10
Tyra Biosciences, Inc. TYRA — 8-K: Results of Operations and Financial Condition
neutral
The company reported initial Phase 2 results for oral dabogratinib, demonstrating a 79% overall response rate and 64% complete response rate, and completed a $400 million financing, but the impact is neutral as the results, although promising, are still early-stage and the financing, while providing additional capital, also represents dilution.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →